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3 (strong). Multiplication of quantity score and intensity score resulted in an IRS ranging from 0 to 12. The optimal cutoff value of IRS was calculated by receiver-operator characteristic (ROC) analysis [18] . The values of area under curve (AUC) at different IRS of APRIL for OS were obtained. The optimal cutoff value of IRS was 3 (Fig. 2D) . So the samples with IRS 0-3 were classified as low APRIL expression and the samples with IRS 4-12 were classified as high APRIL expression, respectively.
Quantitative real-time PCR
Total RNA was extracted with the TRIzol reagent (Invitrogen) according to the manufacturer's instructions, and was reverse transcribed into cDNA using Primescript RT Reagent (Takara). Realtime PCR was performed using a 7500 Real-time PCR System (Applied Biosystems) with SYBR Premix Ex Taq Kit (Takara). The following primers were used: APRIL, forward: 5'-ATTAACGCCACCTCCAAG-3', reverse: 5'-CAGCAGATAAACTCCAGCAT-3'; β-actin, forward: 5'-AGAGCCTCGCCTTTGCCGATCC-3', reverse: 5'-CTGGGCCTCGTCGCCCACATA-3'. TaqMan probes (Genepharma, ShangHai, China) were used to quantify miR-145, and miR-145 expression levels were normalized to snRNA U6. All procedures were performed in triplicate.
Immunoblotting
Cell extracts were collected in a lysis buffer (50 mM Tris-HCl [pH 7.4], 150 mM NaCl, 1 % Triton X-100, 0.1 % SDS, 1 mM EDTA and protease inhibitor cocktail). The cellular protein was size-fractionated by SDS-polyacrylamide gel electrophoresis and transferred to PVDF membranes (Bio-Rad Laboratories). After blocking with PBS containing 5% BSA, the membrane was incubated with the appropriate primary antibody at 4 °C overnight, followed by incubation with HRP-conjugated anti-mouse or antirabbit IgG at room temperature for 2 h. The protein bands were detected using an enhanced chemiluminescence (ECL) detection system following the manufacturer's instructions. The following primary antibodies were used: anti-APRIL, anti-MDM2 (Abcam), anti-Bcl-2, anti-Bcl-xl, anti-Bax, anti-p53, anti-pAKT, anti-AKT, anti-IκBα, anti-p65, anti-GAPDH and anti-H3 (Cell signaling technology). All procedures were performed in triplicate.
Nuclear/cytoplasmic fractionation Nuclear/cytoplasmic lysates were prepared using a Nuclear/Cytosol Fractionation Kit (BioVision). Cells were resuspended with 0.2 ml CEB-A mix containing DTT and protease inhibitors, followed by incubation with 11μl CEB-B for 1min. Then centrifuged and collected the supernatant (cytoplasmic extract). Finally, resuspended the pellet with 100 μl NEB mix, followed by centrifugation and collecting the supernatant (nuclear extract).
Cell proliferation and cytotoxicity assay Cells (2000/well) were seeded into 96-well plates and stained at the indicated time point using the Cell Counting Kit-8 (Dojindo Laboratories), according to the instructions of the manufacturer's instructions. The optical density measured at 450 nm was used as an indicator of cell viability. For cytotoxicity assay, cells were treated with various concentrations of cisplatin (Selleck) dissolved in PBS. All procedures were performed in triplicate.
Colony formation GC cells transfected with the vectors containing APRIL (or the empty vector as a control) were cultured in 6-well plates (3000 cells/well). After adherence, the cells were treated with cisplatin (27 μM) for 8 hours. 
Luciferase reporter assay
The 3'UTR of APRIL containing the wild or mutated miR-145 binding sequences were synthesized by Genescript (Nanjing, China). The sequences were cloned into the pGL3-control vector (Promega) to generate the APRIL 3'UTR reporter. The miRNA mimic negative control (HMC0003) and mimic of miR-145 (HMI0224) were obtained from Sigma. A reporter vector (pNF-κB-Luc) that contained multiple copies of the nuclear factor NF-κB responsive element upstream of the pTAL vector was used for monitoring NF-κB activity (Clontech).
Cells were seeded onto 24-well plates and were tranfected with reporter vectors (0.6 μg/well) together with phRL-TK vectors (0.05 μg/well) (Promega) using Lipofectamine 2000 reagent (Invitrogen) according to the manufacturer's protocol. The phRL-TK vectors were used for standardization of the data. Firefly and Renilla luciferase activities were measured by Dual-Luciferase reporter assay (Promega). All procedures were performed in triplicate.
Tumor xenografts and anticancer chemotherapy in vivo
Male BALB/c nude mice (5 weeks old) were purchased from Vitalriver (Nanjing, China). AGS-NC and AGS-APRIL stably transfected cells were inoculated subcutaneously to form the first-generation xenografts. The xenografts were serially transplanted in nude mice by inoculating tumor fragments (2 × 2 × 2 mm) subcutaneously with a trocar needle. One week after inoculation, each kind of xenografts were devided into chemotherapy group and control group. Twelve mice were used in each group according to the sample estimation with a statistical power of 90%. Control group received saline only. Chemotherapy group received 7.5 mg/kg of cisplatin once per week intraperitoneally. The regimens were performed for 4 weeks [19] . Mice were sacrificed after treatment. The kinetics of tumour formation was assessed by measuring the tumour sizes every 4 days. The tumor volume was calculated using the formula: volume = (width 2 × length)/2.
Heparitinase treatment 10 mU/ml heparitinase (Sigma) prepared in 20 mM Tris-HCl, PH 7.5, containing 0.1 mg/ml BSA and 4 mM CaCl 2 was added into AGS-APRIL cells. Control incubations (AGS-NC and AGS-APRIL cells) were treated identical without the addition of enzyme. All experiments were performed in triplicate.
Statistics
The significance of APRIL expression in primary tumors compared with paired non-tumors was assessed by the paired Wilcoxon test. Probability of differences in OS was ascertained by Kaplan-Meier method, with a log-rank test probe for significance. Univariate and multivariate Cox proportional hazards regression analyses were performed to estimate the hazard ratios (HRs). The cut-off level of APRIL was evaluated by plotting [t, AUC(t)] for different values of follow-up time (t). All the statistical analyses were performed by SPSS software (version 13.0, Chicago, IL). A p-values < 0.05 were considered statistically significant.
Results

APRIL is upregulated in GC and is associated with tumor size and H. pylori infection
We analysed APRIL mRNA expression levels in 159 GC patients and their paired nontumor tissues by real-time PCR. It was shown that APRIL mRNA expression was significantly upregulated in the GC tissues compared to the corresponding adjacent non-tumor samples (Fig. 1A, 1B) . The APRIL expression levels of 6 pairs of typical cases, 5 human GC cell lines and 1 human gastric mucosal cell line were validated by western blotting (Fig. 1C, 1D ). To further confirm APRIL expression levels in tumor cells, not in stroma, IHC was performed. It was shown that tumor cells expressed either high or low APRIL protein, while normal mucosal cells rarely expressed APRIL protein (Fig. 1F) . The distribution of different APRIL expression in tumor cells and mucosal cells was shown in Fig. 1e . The protein levels of APRIL were significantly increased in tumor cells (high 87 cases, low 45 cases and negative 27 cases) and decreased in mucosal cells (high 12 cases, low 27 cases and negative 120 cases) (Fig. 1E) .
In addition, we found that APRIL staining in tumor cells was significantly associated with H. pylori infection and tumor size ( Table 2 ). This was confirmed by the results from real-time PCR analysis ( Table 2) . 
High expression of APRIL is correlated with poor prognosis in cisplatin-treated GC patients
We constructed Kaplan-Meier survival curves to study the relationship between APRIL protein expression and survival after surgical resection. In the analysis of overall 159 GC cases, there was no significant relationship between APRIL protein expression in tumor cells and survival ( Fig. 2A) . In patients receiving 5-FU-based chemotherapy, there was no significant association either (Fig. 2B) . Notably, high levels of APRIL protein in tumor cells were associated with poor survival in those patients with cisplatin-based chemotherapy (Univariate Cox regression HR = 1.593, 95% CI: 1.318-2.240; log-rank P = 0.037) (Fig. 2C) . These results indicated that APRIL might induce cisplatin resistance in GC tumor cells.
Next, we investigated the influence of APRIL expression and other clinicopathological parameters on overall survival using multivariate Cox regression analysis. Our results showed that differentiation and TNM stage were independent factors for overall survival in GC patients (Table 3) . 
APRIL promotes resistance to cisplatin in human GC cells
We chose high APRIL-expression GC cell line SGC7901 and low APRIL-expression GC cell line AGS to generate stable APRIL-knockdown cell line (SGC7901-shRNA) and stable APRILoverexpression cell line (AGS-APRIL). AGS-APRIL cells displayed a 3-fold increase of APRIL protein compared with AGS-NC cells. SGC7901-shRNA cells showed a 91% downregulation of APRIL protein compared with SGC7901-NC cells (Fig. 4A) .
Measurement of IC 50 was performed to evaluate the sensitivity of AGS-APRIL cells or SGC7901-shRNA cells to cisplatin. It was showed that the silence of APRIL in SGC7901 leaded to an increased sensitivity to cisplatin (IC 50 : SGC7901-shRNA, 2.64 (2.38-3.05) μM vs. SGC7901-NC, 4.83 (4.46-5.23) μM). In contrast, overexpression of APRIL in AGS showed an decreased sensitivity to ciaplatin (IC 50 : AGS-APRIL, 37.20 (33.73-41.02) μM vs. AGS-NC, 27.32 (24.86-30.03) μM) (Fig. 3A) .
Next, we conducted time-response curves using the dose of IC 50 for AGS-NC or SGC7901-NC. The response curve of AGS-APRIL showed more resistant to cispaltin than AGS-NC from 24h to 72h, whereas SGC7901-shRNA had a better response curve compared to SGC7901-NC from 12h to 72h (Fig. 3B) .
To further determine the long-term effects of APRIL on cisplatin-inhibited cell proliferation, colony formation assay was performed. As shown in Fig. 3C , although cisplatin induced a dramatic inhibition of colony formation in AGS-NC cells, only a partial inhibition was observed in AGS-APRIL cells when cells were treated with the same concentration of cisplatin (survival rate: mean number of colonies in cisplatin-treated group/ mean number of colonies in saline-treated group). 
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APRIL induces cisplatin resistance via activating NF-κB pathway
As increasing amounts of data demonstrate that the activation of NF-κB pathway plays an indispensible role in APRIL-mediated chronic lymphocytic leukemia B-cell survival [20, 21] , we investigated the relationship between APRIL and NF-κB pathway involved in 
Zhi et al.: APRIL Expression in Gastric Cancer
Cellular Physiology and Biochemistry
Cellular Physiology and Biochemistry
miR-145 regulates APRIL expression through directly targeting its 3'UTR
To understand the regulation of APRIL in GC cells, we used three algorithms (TargetScan, PicTar and miRanda) to predict miRNAs which might target APRIL. Two putative miRNAs (miR-145 and miR-199ab-5p) were figured out. Given that miR-145 has been reported to be downregulated and implicated in suppressing invasion, metastasis and angiogenesis in gastric cancer [25] [26] [27] , we hypothesized that miR-145 downregulated APRIL expression in GC cells. The luciferase reporter assay was employed to validate the hypothesis. Wildtype and mutant APRIL 3'UTR containing putative target sites of miR-145 were cloned into reporter plasmids respectively (Fig. 5A) . The results revealed that miR-145 significantly declined the activity of the luciferase reporter gene fused to the APRIL 3'UTR. Mutation of the putative miR-145 binding sites in the 3'UTR of APRIL abrogated luciferase responsiveness to miR-145 (Fig. 5C ). Western blot showed that APRIL protein levels were inhibited in miR-145 mimics-transfected cells (Fig. 5B) . Furthermore, we confirmed that miR-145 was significantly down-regulated in GC and GC cell lines (Fig. 5D, 5F ) and the level of miR-145 was inversely correlated with APRIL mRNA (Fig. 5E) .
HSPG are required for APRIL-induced cisplatin resistance and NF-κB translocation
To demonstrate the contribution of heparan sulfate proteoglycans (HSPG) in APRILinduced cisplatin resistance, we evaluated IC 50 , time-response curves, colony formation, luciferase activity of pNF-κB-Luc and NF-κB translocation in AGS-APRIL cells treated with heparitinase (Fig. 6 ). As shown in Fig. 6A , APRIL-induced resistance to cisplatin was markedly inhibited by heparitinase (IC50: AGS-APRIL+Heparitinase, 28.21 (25.68-30.99) μM vs. AGS-APRIL, 37.20 (33.73-41.02) μM). In Fig 6B, we used two-way ANOVA to analyze the data. When compared to AGS-APRIL cells, AGS-APRIL+ Heparitinase cells showed more sensitive to cisplatin from 24 h to 72 h (t = 2.867 and P < 0.05 in 24 h, t = 4.135 and P < 0.001 in 48 h, t = 4.685 and P < 0.001 in 72 h). However, when compared to AGS-NC cells, AGS-APRIL+ Heparitinase cells did not get significant differences. Colony formation assay was also performed to determine the long-term effects of heparitinase. As shown in Fig.  6C , heparitinase attenuated APRIL-induced colony formation in AGS-APRIL cells exposure to cisplatin. Luciferase reporter assay confirmed that NF-κB pathway was weakened by heparitinase treatment in AGS-APRIL cells (Fig. 6D) . In addition, the nuclear translocation of NF-KB induced by APRIL was diminished by heparitinase treatment (Fig. 6E) . These results indicated that the effects of APRIL were mediated by HSPG and APRIL-HSPG binding is necessary for NF-KB translocation.
Discussion
The survival of resectable GC has shown some progress by more precise surgery and combining chemotherapy with targeted treatment [28, 29] . However, the improvements are small and confined to ill-defined subgroups, except for HER-2 positive GC. Thus, identification of novel prognostic biomarkers as well as therapeutic targets is urgent for GC patients. In the present study, we identified a novel chemo-resistance biomarker APRIL for gastric cancer, which is a tumor-necrosis factor (TNF) family member and is a novel cytokine crucial in sustaining lymphocytic leukemia B cell survival and proliferation [3, 6] .
The tumor-necrosis factor (TNF) family of 19 ligands and 29 receptors orchestrates a wide range of biological functions [30] . Two new TNF ligands were found via expressed sequence tag (EST) database: APRIL and BAFF [3, 31] . The discovery of the new network between these two TNF ligands and their receptors (TACI, BCMA and BAFF-R) triggered an avalanche of research. Although much effort has focused on BAFF, the functions of APRIL have received less attention. High levels of APRIL mRNA were expressed in cancers of gastrointestinal tract suggesting a close interrelationship between APRIL and gastrointestinal cancers [3] . Recently, some malignant functions of APRIL have been discovered in colorectal cancer [12, 13, 32] . Our previous study explored that knockdown of APRIL promoted apoptosis of gastric cancer cells and down-regulated the receptor tyrosine kinases [15] . In this study, we investigated the roles of APRIL expression in GC progression and prognosis. APRIL mRNA extracted from GC tissues was significantly upregulated compared to the corresponding adjacent non-tumor samples. Given that APRIL is not only expressed in carcinoma cells, but also in immune cells infiltrated in cancer [4] , we further detected APRIL protein expression in tumor cells by IHC. It was shown that tumor cells expressed either high or low APRIL protein, while normal mucosal cells rarely expressed APRIL protein. In addition, we found that APRIL staining in tumor cells was significantly associated with H. pylori infection and tumor size, which was confirmed by the results from real-time PCR analysis. In the analysis of overall 159 GC cases, there was no significant relationship between APRIL protein expression in tumor cells and OS. In patients receiving 5-FU-based chemotherapy, there was no significant association either. When it comes to those patients with cisplatin-based chemotherapy, high levels of APRIL protein in tumor cells were associated with poor OS. These results supported further investigation of a putative functional role for APRIL in clinical cisplatin chemo-resistance. Both in vitro and in vivo assays confirmed that APRIL induced cisplatin resistance in GC tumor cells.
APRIL is shown to bind to TACI and BCMA, but not BAFF-R which only binds to BAFF, and to activate the nuclear factor-κB (NF-κB) pathway [33, 34] . All known receptors have been shown to be expressed on B cells as well as carcinoma cells [35] . On the other hand, APRIL interacts with heparan sulfate proteoglycans (HSPG), which are structurally unrelated to TNF receptors and are likely a third receptor for APRIL [36] [37] [38] . In the present study, we showed that APRIL activated the canonical NF-κB pathway through phosphorylation of AKT. Thus, the NF-κB pathway target genes, such as Bcl-2 and Bcl-xl [21] , were upregulated and contributed to cisplatin resistance. In addition, we also explored the mechanism of regulating APRIL expression in GC cells. We predicted two candidates of putative miRNAs (miR-145 and miR-199ab-5p) using three algorithms (TargetScan, PicTar and miRanda). Given that miR-145 has been reported to be downregulated and implicated in suppressing invasion, metastasis and angiogenesis in gastric cancer [25] [26] [27] , we hypothesized that miR-145 downregulated APRIL expression in GC cells. The luciferase reporter assay validated this hypothesis. Western blot also showed that APRIL protein levels were inhibited in miR-145 mimics-transfected cells. Our data suggested that HSPG function as the main receptor for APRIL in GC cells. Also, our studies showed that the APRIL-HSPG interaction triggers APRIL-mediated NF-KB activation on GC cells.
In conclusion, our results demonstrated that high levels of APRIL expression significantly correlated with unfavorable prognosis in the patients receiving cisplatin-based chemotherapy. The canonical NF-κB pathway was involved in APRIL-induced cisplatin resistance in GC cells. Thus, APRIL may serve as a promising prognostic marker and a therapeutic target for GC. So far, some novel therapeutic agents designed to neutralize APRIL has been tested in clinical trials or in preclinical experimentation [39, 40] . Our study encourages further clinical trials to prove that neutralizing APRIL will be an effective therapy for GC patients.
